$NTRA

Chapman Steven Leonard sold $380K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,742 shares of Natera, Inc. (NTRA) at $218.28 ($0.38M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The main tradable element is sentiment/positioning around insider activity; there is no new company-specific fundamental information in the filing.

02

Market read

Traders may briefly reassess sentiment/technical positioning, but the 10b5-1 designation limits fundamental interpretation.

03

What to watch

The disclosure does not reveal intent beyond the pre-arranged plan; without accompanying buys, it’s hard to infer directional conviction.

Relevance 6/10Novelty 4/10Timing: After-hours/next-session read-through of an SEC Form 4 insider sale (filed 2026-06-05).

Background

This is an SEC Form 4 insider transaction for Natera, reporting an officer/director open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and president Chapman Steven Leonard sold $380.3K of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine insider transaction disclosure and explicitly notes a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Minimal; single-company insider sale without new operational/regulatory/clinical catalysts.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can coincide with diversification or liquidity needs and may not reflect bearish expectations; the market may overreact to the headline.

Key entities

  • Natera, Inc.

    US-listed company whose CEO/president reported an open-market share sale under a 10b5-1 plan.

  • Chapman Steven Leonard

    CEO and president who sold 1,742 shares at ~$218.28/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.